ECONOMIC EVALUATION OF VANCOMYCIN VERSUS DAPTOMYCIN VERSUS TEICOPLANIN IN THE MANAGEMENT OF BACTEREMIA IN JORDAN: A STUDY FROM PAYER PERSPECTIVE
Author(s)
Montaser Bilbisi, MD1, Heba Al Helou, MSc2, Rawan Alfroukh, MSc3, Farah Radaydeh, MSc4, Nimer Alkhatib, PhD4.
1Infectious diseases and infection control, Abdali Medical Center, Amman, Jordan, 2MS Pharma, Amman, Jordan, 3Path economics,LLC, Amman, Jordan, 4College of pharmacy, Al-Zaytoonah University of Jordan, Amman, Jordan.
1Infectious diseases and infection control, Abdali Medical Center, Amman, Jordan, 2MS Pharma, Amman, Jordan, 3Path economics,LLC, Amman, Jordan, 4College of pharmacy, Al-Zaytoonah University of Jordan, Amman, Jordan.
OBJECTIVES: Daptomycin is a therapeutic option for the management of bacteremia. Despite its clinical benefits, its high upfront acquisition cost has raised uncertainty regarding its cost-effectiveness compared with conventional alternatives such as vancomycin and teicoplanin. To date, no economic evaluation comparing these treatments has been conducted in the Jordanian healthcare setting.
METHODS: A cost simulation model was developed with a 42-day time horizon from payer's perspective. Comparative effectiveness data, including risks of failing to achieve therapeutic drug levels and treatment success rates, were obtained from published literature and validated by local clinical experts. The model incorporated local drug acquisition, administration, monitoring and follow-up, hospitalization, and healthcare resource utilization costs, including management of adverse events, based on local clinical practice. A base-case analysis was conducted using mean input values to estimate cost per patient treated for bacteremia. One-way sensitivity analysis (OWSA) assessed the impact of treatment duration on total costs. All results were reported in Jordanian Dinars (JOD), where 1 JOD equals USD 1.41.
RESULTS: In the base case analysis, assuming a mean treatment duration of 14 days, vancomycin was associated with the highest cost at JOD 13,147 per patient. Daptomycin resulted in the lowest cost at JOD 10,240 per patient, followed by teicoplanin at JOD 11,624 per patient. OWSA demonstrated that daptomycin remained the least costly option when treatment duration did not exceed 37 days. For treatment durations beyond 37 days, teicoplanin became the least costly alternative (JOD 12,198 per patient). Vancomycin was consistently associated with higher costs due to a greater risk of failing to achieve therapeutic levels.
CONCLUSIONS: Daptomycin was associated with the lowest cost, reduced risk of subtherapeutic exposure, and lower healthcare utilization for treatment durations up to 37 days. For prolonged treatment beyond 37 days, teicoplanin emerged as the most cost-efficient option, while vancomycin was not cost-saving across evaluated scenarios.
METHODS: A cost simulation model was developed with a 42-day time horizon from payer's perspective. Comparative effectiveness data, including risks of failing to achieve therapeutic drug levels and treatment success rates, were obtained from published literature and validated by local clinical experts. The model incorporated local drug acquisition, administration, monitoring and follow-up, hospitalization, and healthcare resource utilization costs, including management of adverse events, based on local clinical practice. A base-case analysis was conducted using mean input values to estimate cost per patient treated for bacteremia. One-way sensitivity analysis (OWSA) assessed the impact of treatment duration on total costs. All results were reported in Jordanian Dinars (JOD), where 1 JOD equals USD 1.41.
RESULTS: In the base case analysis, assuming a mean treatment duration of 14 days, vancomycin was associated with the highest cost at JOD 13,147 per patient. Daptomycin resulted in the lowest cost at JOD 10,240 per patient, followed by teicoplanin at JOD 11,624 per patient. OWSA demonstrated that daptomycin remained the least costly option when treatment duration did not exceed 37 days. For treatment durations beyond 37 days, teicoplanin became the least costly alternative (JOD 12,198 per patient). Vancomycin was consistently associated with higher costs due to a greater risk of failing to achieve therapeutic levels.
CONCLUSIONS: Daptomycin was associated with the lowest cost, reduced risk of subtherapeutic exposure, and lower healthcare utilization for treatment durations up to 37 days. For prolonged treatment beyond 37 days, teicoplanin emerged as the most cost-efficient option, while vancomycin was not cost-saving across evaluated scenarios.
Conference/Value in Health Info
2026-11, ISPOR Europe 2026, Vienna, Austria
Value in Health, Volume 29, Issue 12S
Code
EE188
Topic
Clinical Outcomes, Economic Evaluation, Health Technology Assessment
Topic Subcategory
Cost/Cost of Illness/Resource Use Studies
Disease
Infectious Disease (non-vaccine), No Additional Disease & Conditions/Specialized Treatment Areas